Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Matinas BioPharma (MTNB) Reports In-Line Q4 EPS
March 29, 2021 6:33 AM EDTMatinas BioPharma (NYSE: MTNB) reported Q4 EPS of ($0.03), in-line with the analyst estimate of ($0.03).
2020 was a year of significant progress and timely execution for Matinas, despite the ongoing global pandemic. The completion of the head-to-head ENHANCE-IT trial of LYPDISO vs. Vascepa® and the results which support the potential for LYPDISO to demonstrate a superior cardioprotective effect to Vascepa®, have positioned us to identify and potentially secure a global partner for the continued development of this promising, next-generation drug, commented Jerome D. Jabbour, Chief Executive Officer of Matinas. This... More
